Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Haematologica

Volumn 93, Issue 1, 2008, Pages

  Kalff, A ^a   Shortt, J ^a   Farr, J ^a   McLennan, R ^b   Lui, A ^c   Scott, J ^c   Spencer, A ^a  

^a ALFRED HOSPITAL   (Australia)

^b GEELONG HOSPITAL   (Australia)

^c Novartis Oncology ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTROLYTE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; PANOBINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CASE REPORT; CHEMISTRY; DISEASE COURSE; DRUG ANTAGONISM; FATALITY; HUMAN; MALE; METABOLISM; MIDDLE AGED; TUMOR LYSIS SYNDROME;

DISEASE PROGRESSION; ELECTROLYTES; ENZYME INHIBITORS; FATAL OUTCOME; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TUMOR LYSIS SYNDROME;

EID: 42449156334     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.11933     Document Type: Article

References (6)

1. Beck J, Fischer T, Rowinsky E, et al. Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589: a novel histone deacetylase inhibitor [abstract]. Proc Amer Soc Clin Oncol 2004;23:20. Abstract 3025.
2. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;104:1768-1776.
3. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005:280:26729-26734.
4. Cairo M, Bishop M. Tumour Lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
5. Wiernik PH, Banks PL, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1995:79:313-319.
6. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 1994;8:1842-1846.